11:13 AM EST - WPD Pharmaceuticals Inc. : Announced that a recently published study confirms the high therapeutic potential of IL-13RA2- and EphA2 receptor-targeted cytotoxins in the WPD101 drug candidate. The study found the combination of these cytotoxins as a highly effective anticancer therapy in dogs with spontaneous intracranial gliomas. WPD Pharmaceuticals Inc.
shares C.WBIO are trading unchanged at $0.38.
